Pseudomonas aeruginosa

Pseudomonas Aeruginosa Pneumonia Pipeline Review, H2 2020 - Therapeutic Assessment of 4 Companies & 7 Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Monday, November 2, 2020
Infectious diseases, Pharmaceutical, Health, Gram-negative bacteria, Pseudomonadales, Antibiotic-resistant bacteria, Pseudomonas aeruginosa, Pseudomonas

The "Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020

Retrieved on: 
Wednesday, October 21, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious diseases, Clinical trials, Bacteria, Gram-negative bacteria, Chemical compounds, Organic compounds, Enterobacteriaceae, Beta-lactam antibiotics, Beta-lactamase, Antibiotic-resistant bacteria, Carbapenem, Thiazoles, Pseudomonas aeruginosa, Cefepime, Cefepime-Taniborbactam, Venatorx Pharmaceuticals, Inc.

When combined with cefepime, a fourth generation cephalosporin antibiotic, taniborbactam drives antimicrobial activity against gram-negative bacteria including carbapenemase-producing-Enterobacterales and Pseudomonas aeruginosa including multi-drug resistance strains.

Key Points: 
  • When combined with cefepime, a fourth generation cephalosporin antibiotic, taniborbactam drives antimicrobial activity against gram-negative bacteria including carbapenemase-producing-Enterobacterales and Pseudomonas aeruginosa including multi-drug resistance strains.
  • This includes pathogens that produce extended-spectrum beta-lactamases, AmpC beta-lactamases, AmpC, KPC, OXA, NDM, and VIM.
  • Venatorx is currently enrolling a Phase 3 clinical trial ( ClinicalTrials.gov NCT03840148 ) of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs).
  • Venatorx Pharmaceuticals is a private pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections

Retrieved on: 
Thursday, October 15, 2020
Bacteria, Medical specialties, Microbiology, Pathogenic bacteria, Gram-negative bacteria, Pseudomonadales, Bacterial diseases, Bacteriophage, Biology, Pseudomonas aeruginosa, Pseudomonas, Staphylococcus aureus

to reflect the manner in which phage attack dangerous pathogens, will be our Company's first clinical trial to evaluate a phage-based therapy as a potential treatment for Pseudomonas aeruginosa airway infections.

Key Points: 
  • to reflect the manner in which phage attack dangerous pathogens, will be our Company's first clinical trial to evaluate a phage-based therapy as a potential treatment for Pseudomonas aeruginosa airway infections.
  • Barring worsening COVID-19 conditions, Armata expects to initiate the SAD cohort by the end of this year.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program

Retrieved on: 
Wednesday, October 14, 2020
Medical specialties, Gram-negative bacteria, Pseudomonadales, Branches of biology, RTT, Microbiology, Cyclic peptides, Channelopathies, Cystic fibrosis, Pseudomonas aeruginosa, Pseudomonas, Murepavadin

OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.

Key Points: 
  • OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.
  • The companys lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
  • Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN).
  • CARB-X is investing up to $480 million from 2016-2022 to support innovative antibiotics and other therapeutics, vaccines and other prevention approaches, and rapid diagnostics.

Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conference

Retrieved on: 
Wednesday, October 7, 2020
Cystic fibrosis, Medical specialties, Branches of biology, RTT, Ion channels, Channelopathies, Pseudomonas aeruginosa, Eric Sorscher, CFTR inhibitory factor

The randomized, double-blind, placebo-controlled, multiple ascending dose-escalation study (NCT04279769) is exploring CB-280 versus placebo in adults with cystic fibrosis and chronic infection with Pseudomonas aeruginosa who are stable on cystic fibrosis medications, including cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

Key Points: 
  • The randomized, double-blind, placebo-controlled, multiple ascending dose-escalation study (NCT04279769) is exploring CB-280 versus placebo in adults with cystic fibrosis and chronic infection with Pseudomonas aeruginosa who are stable on cystic fibrosis medications, including cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
  • Enrollment in this study is ongoing and Calithera expects to share interim data in 2021.
  • The poster presentation includes preclinical study results which suggest CB-280 significantly improved lung function and reduced Pseudomonas aeruginosa colony-forming units in pre-clinical models.
  • CB-280 is the first arginase inhibitor to be evaluated for the treatment of cystic fibrosis, said Susan Molineaux, PhD, president and chief executive officer of Calithera.

Armata Pharmaceuticals to Present at the Virtual 2020 World Antimicrobial Resistance Congress

Retrieved on: 
Tuesday, September 29, 2020
Medical specialties, Bacteria, Articles, Pathogenic bacteria, Gram-negative bacteria, Pseudomonadales, Bacteriophage, Biology, Pseudomonas aeruginosa, Staphylococcus aureus, Antimicrobial resistance, Pseudomonas

In its sixth year, the Congress will attract more than 700 attendees from over 50 countries and features more than 250 speakers.

Key Points: 
  • In its sixth year, the Congress will attract more than 700 attendees from over 50 countries and features more than 250 speakers.
  • It is the world's largest and most commercially focused gathering of antimicrobial resistance stakeholders globally.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

MicroGold® Dual-Action Disinfectant & Antimicrobial Tested and Proven Effective to Kill the COVID-19 Virus

Retrieved on: 
Tuesday, September 22, 2020
Hygiene, Bactericides, Disinfectant, Antimicrobial, Pseudomonas aeruginosa, Severe acute respiratory syndrome coronavirus, Microbiology, Organisms, Branches of biology

POWAY, Calif., Sept. 22, 2020 /PRNewswire/ --MicroGold Dual-Action Disinfectant & Antimicrobial kills SARS-CoV-2 associated with COVID-19, according to independent lab testing reviewed by the U.S. Environmental Protection Agency .

Key Points: 
  • POWAY, Calif., Sept. 22, 2020 /PRNewswire/ --MicroGold Dual-Action Disinfectant & Antimicrobial kills SARS-CoV-2 associated with COVID-19, according to independent lab testing reviewed by the U.S. Environmental Protection Agency .
  • Distributed by Granite Gold Inc. (GGI) and powered by MonoFoil, MicroGold Dual-Action Disinfectant & Antimicrobial (EPA Reg.
  • Testing conducted on a live strain of SARS-CoV-2 was found to kill the virus in three minutes.
  • MicroGold Dual-Action Disinfectant & Antimicrobial kills 99.9% of viruses and bacteria, including SARS-CoV-2 associated with COVID-19, human rotavirus, pseudomonas aeruginosa, salmonella enterica and staphylococcus aureus, when used as directed.

Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing

Retrieved on: 
Wednesday, September 16, 2020
Articles, Branches of biology, Beta-lactam antibiotics, Drugs, Ceftolozane/tazobactam, Beta-lactamase inhibitors, Tazobactam, Beta-lactamase, Antimicrobial resistance, DNA sequencing, Pseudomonas aeruginosa, Karen Bush

To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014.

Key Points: 
  • To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014.
  • Findings demonstrate the potential of Next-Generation Sequencing (NGS) to investigate mechanisms of resistance by analyzing whole-genome sequencing data from P. aeruginosa isolates that developed resistance under treatment with ceftolozane-tazobactam.
  • The researchers propose extending ceftolozane-tazobactam infusions as a potential protective measure against acquired mutational resistance.
  • The present study is the result of an ongoing collaboration between Ares Genetics and the Johns Hopkins University School of Medicine, with the goal of investigating the diagnostic potential of NGS for antimicrobial susceptibility testing.

ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development

Retrieved on: 
Monday, July 20, 2020
Medical specialties, Health, Infectious diseases, Hospital-acquired infection, Pseudomonas aeruginosa, Bacteremia, Pneumonia, Ventilator-associated pneumonia, Infection, Urinary tract infection, Carbapenem, Neonatal infection

This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met.

Key Points: 
  • This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met.
  • Any funding beyond the initial $4.9 million is at the sole discretion of CARB-X and subject to available funds.
  • At ContraFect, we remain committed to developing superior therapeutic agents with the potential to improve clinical outcomes and save lives.
  • Invasive P. aeruginosa infections, including ventilator-associated pneumonia, blood stream infections, complicated urinary tract infections, and infections following surgery carry some of the highest rates of mortality among hospital acquired infections.

ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)

Retrieved on: 
Wednesday, June 17, 2020
Drugs, Medical specialties, RTT, Medicine, Fluoroquinolone antibiotics, Otologicals, Pediatrics, Otitis externa, Ciprofloxacin/dexamethasone, Ciprofloxacin, Pseudomonas aeruginosa, Otitis

"OTIPRIO provides an important option to treat patients, as young as six months old, with a single-dose antibiotic administered right in the doctor's office."

Key Points: 
  • "OTIPRIO provides an important option to treat patients, as young as six months old, with a single-dose antibiotic administered right in the doctor's office."
  • Acute otitis externa (AOE), also known as swimmer's ear, is a common condition involving infection and inflammation of the external ear canal typically caused by bacterial infection.
  • OTIPRIO is a sterile, preservative-free, otic suspension of 6 percent ciprofloxacin administered as a single-dose by a healthcare professional.
  • The treatment of acute otitis externa in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.